Data Dive Into NK-1 Antagonists & Carboplatin
from OncoPharm Hosted by John Bossaer
ASCO's updated 2017 antiemetic guidelines recommend NK-1 antagonists to prevent CINV with standard Q 3 week carboplatin (i.e. AUC 5-6), but how good are the data to support that? We dive into the supporting data.
Embed this episode
No transcript yet.
Frequently asked questions
How long is this episode of OncoPharm?
This episode is 17 minutes long.
When was this OncoPharm episode published?
This episode was published on November 7, 2019.
Can I download this OncoPharm episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.